These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1412 related items for PubMed ID: 33916864

  • 21. The prognostic value of HRCT in myositis-associated interstitial lung disease.
    Tanizawa K, Handa T, Nakashima R, Kubo T, Hosono Y, Aihara K, Ikezoe K, Watanabe K, Taguchi Y, Hatta K, Oga T, Chin K, Nagai S, Mimori T, Mishima M.
    Respir Med; 2013 May; 107(5):745-52. PubMed ID: 23485097
    [Abstract] [Full Text] [Related]

  • 22. Clinical Heterogeneity of Interstitial Lung Disease in Polymyositis and Dermatomyositis Patients With or Without Specific Autoantibodies.
    Chen F, Li S, Wang T, Shi J, Wang G.
    Am J Med Sci; 2018 Jan; 355(1):48-53. PubMed ID: 29289262
    [Abstract] [Full Text] [Related]

  • 23. Prognostic values of anti-Ro52 antibodies in anti-MDA5-positive clinically amyopathic dermatomyositis associated with interstitial lung disease.
    Xu A, Ye Y, Fu Q, Lian X, Chen S, Guo Q, Lu LJ, Dai M, Lv X, Bao C.
    Rheumatology (Oxford); 2021 Jul 01; 60(7):3343-3351. PubMed ID: 33331866
    [Abstract] [Full Text] [Related]

  • 24. Tofacitinib for recurrence of antimelanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis after remission: A case report.
    Ishikawa Y, Kasuya T, Fujiwara M, Kita Y.
    Medicine (Baltimore); 2020 Sep 11; 99(37):e21943. PubMed ID: 32925726
    [Abstract] [Full Text] [Related]

  • 25. Early initiation of plasma exchange therapy for a patient with anti-MDA5 autoantibody-positive dermatomyositis developing rapidly progressive interstitial lung disease.
    Sasaki N, Ishii A, Kurabayashi T, Sugiyama M, Izumi Y, Nakagome Y, Hirano K, Sasaki S, Kondo Y, Nogi S, Nishikawa A, Hosono Y, Yamada C, Sato S.
    Mod Rheumatol Case Rep; 2021 Jan 11; 5(1):87-94. PubMed ID: 33048020
    [Abstract] [Full Text] [Related]

  • 26. Clinical differences between interstitial lung disease associated with clinically amyopathic dermatomyositis and classic dermatomyositis.
    Mukae H, Ishimoto H, Sakamoto N, Hara S, Kakugawa T, Nakayama S, Ishimatsu Y, Kawakami A, Eguchi K, Kohno S.
    Chest; 2009 Nov 11; 136(5):1341-1347. PubMed ID: 19581351
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. The Role of Myositis-Specific Autoantibodies and the Management of Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: A Systematic Review.
    Teel A, Lu J, Park J, Singh N, Basharat P.
    Semin Arthritis Rheum; 2022 Dec 11; 57():152088. PubMed ID: 36116345
    [Abstract] [Full Text] [Related]

  • 29. Myositis-specific antibodies and clinical characteristics in patients with autoimmune inflammatory myopathies: reported by the Argentine Registry of Inflammatory Myopathies of the Argentine Society of Rheumatology.
    Gómez GN, Pérez N, Braillard Poccard A, Gómez RA, Costi AC, García MA, Viola M, Benitez A, Aciar MM, Crespo Espíndola M, Yucra D, Cosatti MA, Pisoni C, Capelusnik D, Lojo MN, Barrios BI, Rivero M, Kisluk B, Granel A.
    Clin Rheumatol; 2021 Nov 11; 40(11):4473-4483. PubMed ID: 34159491
    [Abstract] [Full Text] [Related]

  • 30. Anti-Ro52 antibodies are associated with the prognosis of adult idiopathic inflammatory myopathy-associated interstitial lung disease.
    Gui X, Shenyun S, Ding H, Wang R, Tong J, Yu M, Zhao T, Ma M, Ding J, Xin X, Qiu Y, Qiu X, Zhang Y, Cao M, Huang M, Cao M, Dai J, Cai H, Xiao Y.
    Rheumatology (Oxford); 2022 Nov 02; 61(11):4570-4578. PubMed ID: 35148366
    [Abstract] [Full Text] [Related]

  • 31. Soluble CD206 levels correlate with disease deterioration and predict prognosis of anti-MDA5 antibody-positive dermatomyositis related interstitial lung disease.
    Li Y, Liu X, Tian M, Zou R, Gao Y, Huang M, Zhou K, Cao M, Cai H.
    Clin Respir J; 2023 Jun 02; 17(6):507-515. PubMed ID: 37041007
    [Abstract] [Full Text] [Related]

  • 32. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
    Yoshida N, Okamoto M, Kaieda S, Fujimoto K, Ebata T, Tajiri M, Nakamura M, Tominaga M, Wakasugi D, Kawayama T, Kuwana M, Mimori T, Ida H, Hoshino T.
    Respir Investig; 2017 Jan 02; 55(1):24-32. PubMed ID: 28012490
    [Abstract] [Full Text] [Related]

  • 33. Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment.
    Mimori T, Nakashima R, Hosono Y.
    Curr Rheumatol Rep; 2012 Jun 02; 14(3):264-74. PubMed ID: 22367479
    [Abstract] [Full Text] [Related]

  • 34. Myositis-specific autoantibodies in dermatomyositis/polymyositis with interstitial lung disease.
    Li L, Wang H, Wang Q, Wu C, Liu C, Zhang Y, Cheng L, Zeng X, Zhang F, Li Y.
    J Neurol Sci; 2019 Feb 15; 397():123-128. PubMed ID: 30616054
    [Abstract] [Full Text] [Related]

  • 35. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies.
    Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD.
    J Am Acad Dermatol; 2006 Apr 15; 54(4):597-613. PubMed ID: 16546580
    [Abstract] [Full Text] [Related]

  • 36. Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease.
    Gono T, Kaneko H, Kawaguchi Y, Hanaoka M, Kataoka S, Kuwana M, Takagi K, Ichida H, Katsumata Y, Ota Y, Kawasumi H, Yamanaka H.
    Rheumatology (Oxford); 2014 Dec 15; 53(12):2196-203. PubMed ID: 24970922
    [Abstract] [Full Text] [Related]

  • 37. Clinical significance of myositis-specific autoantibody profiles in Japanese patients with polymyositis/dermatomyositis.
    Temmoku J, Sato S, Fujita Y, Asano T, Suzuki E, Kanno T, Furuya MY, Matsuoka N, Kobayashi H, Watanabe H, Koga T, Shimizu T, Kawakami A, Migita K.
    Medicine (Baltimore); 2019 May 15; 98(20):e15578. PubMed ID: 31096460
    [Abstract] [Full Text] [Related]

  • 38. Incidence and impact of interstitial lung disease and malignancy in patients with polymyositis, dermatomyositis, and clinically amyopathic dermatomyositis: a retrospective cohort study.
    Ikeda S, Arita M, Misaki K, Mishima S, Takaiwa T, Nishiyama A, Ito A, Furuta K, Yokoyama T, Tokioka F, Noyama M, Yoshioka H, Ishida T.
    Springerplus; 2015 May 15; 4():240. PubMed ID: 26101728
    [Abstract] [Full Text] [Related]

  • 39. Association of Serum Soluble CD163 with Polymyositis and Dermatomyositis, Especially in Anti-MDA5 Antibody-positive Cases.
    Kawasumi H, Katsumata Y, Nishino A, Hirahara S, Kawaguchi Y, Kuwana M, Yamanaka H.
    J Rheumatol; 2018 Jul 15; 45(7):947-955. PubMed ID: 29657141
    [Abstract] [Full Text] [Related]

  • 40. Clinical features of anti-synthetase syndrome associated interstitial lung disease: a retrospective cohort in China.
    Zhan X, Yan W, Wang Y, Li Q, Shi X, Gao Y, Ye Q.
    BMC Pulm Med; 2021 Feb 12; 21(1):57. PubMed ID: 33579248
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 71.